Pub. Date : 2018 Dec
PMID : 30431011
9 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 2 | The results showed that ulixertinib, at non-toxic concentrations, significantly reversed ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily G member 2 (ABCG2)-mediated MDR. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 3 | The results showed that ulixertinib, at non-toxic concentrations, significantly reversed ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily G member 2 (ABCG2)-mediated MDR. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 4 | Similarly, in ABCG2-overexpressing cells, ulixertinib inhibited the efflux activity of ABCG2 and reversed resistance to substrate anticancer drugs. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 5 | Similarly, in ABCG2-overexpressing cells, ulixertinib inhibited the efflux activity of ABCG2 and reversed resistance to substrate anticancer drugs. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 6 | Mechanistic investigations revealed that ulixertinib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concentration-dependent manner, and the in silico docking study predicted that ulixertinib could interact with the substrate-binding sites of both ABCB1 and ABCG2. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 7 | Mechanistic investigations revealed that ulixertinib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concentration-dependent manner, and the in silico docking study predicted that ulixertinib could interact with the substrate-binding sites of both ABCB1 and ABCG2. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 8 | Mechanistic investigations revealed that ulixertinib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concentration-dependent manner, and the in silico docking study predicted that ulixertinib could interact with the substrate-binding sites of both ABCB1 and ABCG2. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 9 | Our finding provides a clue into a novel treatment strategy: a combination of ulixertinib with anticancer drugs to attenuate MDR mediated by ABCB1 or ABCG2 in cancer cells overexpressing these transporters. | ulixertinib | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |